Weight Loss Investigational 🔥 Trending

Amycretin

A Novo Nordisk investigational co-agonist targeting GLP-1 and amylin pathways, now closely watched as a next-wave obesity candidate.

GLP-1AmylinObesityInvestigationalNovo Nordisk

Also referenced as: NNC0487-0111

Also appears in: Hormone

Status
Investigational

This compound has a genuine development or study trail, but it is not an approved routine drug.

Category
Weight Loss

Primary lane: Weight Loss. Also surfaces under Hormone for browsing and discovery.

Aliases
1

NNC0487-0111

Signal depth
Medium

No FDA label signal · 21 trials · 17 PubMed results

Promising
Research evidence

Amycretin has name-matched human trials with published or reported controlled evidence, but is not FDA-approved. The research is real and ongoing — treat findings as developing rather than settled.

Amycretin has 21 name-matched clinical trials (highest phase: Phase 3) and 17 PubMed-indexed publications and is not FDA-approved. Human trials are registered but none have posted results yet.

Human data
Phase 3
Trial quality
Large RCT
Outcomes
Clinical outcomes
Replication
Meta-analysis
Literature
High-impact
PHASE3 · Randomized A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity PHASE3 · Randomized AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose Weight PHASE3 · Randomized AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight The Lancet · 54 citations Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study The Lancet · 31 citations Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind, randomised, placebo-controlled trial EBioMedicine · 12 citations The effect of amycretin, a unimolecular glucagon-like peptide-1 and amylin receptor agonist, on body weight and metabolic dysfunction in mice and rats
Evidence history

Re-checked nightly against the registries — tracked since 2026-07-09. No band changes yet.

Grades evidence strength, not efficacy or safety. Research-use context; not medical advice. Graded 2026-07-13 from PubMed, ClinicalTrials.gov, ISRCTN, openFDA, Health Canada, and OpenAlex — computed deterministically and refreshed nightly, with a retraction check. How we grade →

What amycretin is

Amycretin is an investigational single-molecule GLP-1 and amylin receptor agonist being developed by Novo Nordisk for obesity and related metabolic disease.

Why it matters

It is one of the clearer examples of where the obesity pipeline is heading after first-generation GLP-1 therapies. Instead of just extending incretin pharmacology, amycretin combines GLP-1 signaling with amylin-linked satiety in a single molecule.

Regulatory context

Amycretin is not FDA approved. The public human evidence base is still early relative to drugs like semaglutide or tirzepatide, but the compound is now important enough that it belongs in any current obesity-peptide library.

Practical reading note

Amycretin gets talked about like a future blockbuster, but the safest framing is still: high-interest pipeline drug, not established therapy.